Study guide
8.4 Respiratory Infections & Bronchiectasis
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
8.4 Respiratory Infections & Bronchiectasis
Key Takeaways Explain This Topic AI
Streptococcus pneumoniae remains the most frequent bacterial cause of CAP, typically presenting with high rigors, rust-coloured sputum, and lobar consolidation; atypical organisms display signature clinical clues such as Legionella (hyponatraemia, diarrhoea, cooling towers) and Mycoplasma (cold haemolytic anaemia, erythema multiforme).
Pneumocystis jirovecii pneumonia (PJP) affects immunocompromised patients (HIV CD4 < 200 cells/mcL), presenting with exertional desaturation, clear chest auscultation, high LDH, and requiring high-dose co-trimoxazole plus adjunctive steroids if PaO2 < 9.3 kPa.
The CURB-65 score stratifies 30-day CAP mortality: Confusion (AMTS <= 8), Urea > 7.0 mmol/L, Respiratory rate >= 30/min, Blood pressure (SBP < 90 or DBP <= 60 mmHg), and Age >= 65; scores of 3-5 demand urgent inpatient admission and IV co-amoxiclav plus IV clarithromycin.
Bronchiectasis diagnosis is established by high-resolution CT demonstrating the 'signet ring' sign (bronchoarterial diameter ratio > 1.0) and lack of peripheral bronchial tapering; aetiologies include cystic fibrosis (upper lobe), Kartagener syndrome (lower lobe with dextrocardia), and ABPA.
First isolation of Pseudomonas aeruginosa in bronchiectasis mandates an immediate, aggressive eradication attempt with oral ciprofloxacin or IV antipseudomonal beta-lactam combined with nebulised colistimethate, alongside twice-daily chest physiotherapy.
Last updated: September 2026
Lower respiratory tract infections and chronic suppurative airway diseases feature heavily across both papers of the MRCP(UK) Part 1 examination. Candidates must master the distinct pathogen-specific clinical phenotypes of community-acquired pneumonia (CAP), risk stratification using the validated CURB-65 prognostic tool, the diagnosis and emergency management of opportunistic Pneumocystis jirovecii pneumonia, and the aetiological investigation and multidisciplinary management of bronchiectasis.
1. Community-Acquired Pneumonia: Pathogen-Specific Signatures
Correct antimicrobial selection hinges on recognizing distinguishing epidemiological, extrapulmonary, and laboratory clues pointing to specific microbial culprits.
1. Typical Bacterial Pathogens
Streptococcus pneumoniae (Pneumococcus): Gram-positive lancet-shaped diplococci. The most frequent causative pathogen ( 50 – 60 % 50\text{–}60\% 50 – 60% of CAP cases). Classic presentation: sudden onset of high fever, shaking rigors, pleuritic chest pain, tachypnoea, rust-coloured sputum (mixture of lysed erythrocytes, neutrophils, and fibrin), herpes labialis, and dense lobar consolidation on chest radiography. Rapid urinary antigen detection has a sensitivity of 70 – 80 % 70\text{–}80\% 70 – 80% and persists despite prior antibiotic initiation.
Staphylococcus aureus : Gram-positive cocci in clusters. Infrequent in primary CAP but classically complicates post-influenza viral pneumonia . Produces an aggressive, necrotizing pneumonia with rapid cavitation, pneumatoceles (thin-walled cystic spaces), spontaneous pneumothorax, and empyema. If Methicillin-Resistant S. aureus (MRSA) is suspected, linezolid or vancomycin must be added.
Klebsiella pneumoniae : Encapsulated Gram-negative bacillus. Classically affects individuals with chronic alcohol misuse, severe malnutrition, or diabetes mellitus . Characterized by severe necrotizing pneumonia predominantly involving the right upper lobe, producing cavitation, bulging of the interlobar fissure on CXR, and thick, viscous "redcurrant jelly" sputum .
Pseudomonas aeruginosa : Non-fermenting Gram-negative bacillus. Common in patients with structural lung disease (severe bronchiectasis, cystic fibrosis, advanced COPD with frequent steroid/antibiotic courses). Requires antipseudomonal β \beta β -lactams (piperacillin-tazobactam, ceftazidime, meropenem) plus an aminoglycoside or fluoroquinolone.
2. Atypical & Opportunistic Pathogens
Legionella pneumophila : Fastidious aerobic Gram-negative rod that thrives intracellularly within alveolar macrophages. Transmitted via inhalation of contaminated aerosols from colonized man-made water systems (hotel air conditioning cooling towers, spa pools, hospital showers). Classic clinical triad: High spiking fevers with relative bradycardia ( Faget's sign ), gastrointestinal symptoms ( profuse watery diarrhoea , severe abdominal cramps), and neurological abnormalities (confusion, encephalopathy, ataxia). Laboratory clues: Marked hyponatraemia (secondary to SIADH and renal tubulopathy), hypophosphataemia, elevated transaminases, lymphopenia , and microscopic haematuria. Diagnosis: Urinary antigen test (detects L. pneumophila serogroup 1, accounting for > 80 % > 80\% > 80% of clinical cases). Treatment: IV fluoroquinolones (levofloxacin) or macrolides (clarithromycin).
Mycoplasma pneumoniae : Extracellular organism lacking a peptidoglycan cell wall (intrinsically resistant to all β \beta β -lactam antibiotics!). Common in children, university students, and military recruits. Insidious onset of headache, sore throat, dry cough, and low-grade fever. Extrapulmonary manifestations: Cold autoimmune haemolytic anaemia (AIHA) mediated by IgM autoantibodies directed against the erythrocyte I antigen (cold agglutinins causing acrocyanosis and Coombs-positive haemolysis), erythema multiforme (targetoid iris lesions), Stevens-Johnson syndrome, myocarditis, Guillain-Barré syndrome, and transverse myelitis. Diagnosis: PCR on throat swab. Treatment: Macrolides, doxycycline, or respiratory fluoroquinolones.
Chlamydia (Chlamydophila) psittaci : Transmitted by psittacine birds (parrots, parakeets, pigeons). Presents with high fever, dry cough, severe headache, hepatosplenomegaly, and macular rash (Horder's spots). Treatment: Doxycycline.
Coxiella burnetii (Q Fever): Zoonosis acquired from cattle, sheep, and goats (contact with placenta/amniotic fluid during unpasteurized milk ingestion or calving). Characterized by high fevers, severe headache, abnormal liver function tests, and culture-negative endocarditis. Treatment: Doxycycline.
Pneumocystis jirovecii (PJP / PCP): Atypical unicellular fungus. Classically affects immunocompromised hosts, notably HIV-infected patients with CD 4 count < 200 cells/ μ L \text{CD}_4 \text{ count} < 200\text{ cells/}\mu\text{L} CD 4 count < 200 cells/ μ L , or those on potent immunosuppressants. Clinical presentation: Subacute progressive exertional breathlessness, dry cough, and fever. Physical examination may reveal completely normal lung auscultation despite severe, life-threatening exertional oxygen desaturation . Investigations: CXR shows bilateral perihilar ground-glass infiltrates with sparing of lung apices and costophrenic angles. Markedly elevated serum lactate dehydrogenase (LDH). Definitive diagnosis: Sputum induction or bronchoalveolar lavage stained with Grocott's methenamine silver (GMS) stain revealing cup-shaped cysts, or quantitative PCR. Therapy: High-dose oral or IV co-trimoxazole (trimethoprim-sulfamethoxazole 15 – 20 mg/kg/day 15\text{–}20\text{ mg/kg/day} 15 – 20 mg/kg/day of trimethoprim component) for 21 days. Adjunctive systemic corticosteroids (oral prednisolone or IV methylprednisolone) MUST be initiated concurrently if room air PaO 2 < 9.3 kPa \text{PaO}_2 < 9.3\text{ kPa} PaO 2 < 9.3 kPa ( < 70 mmHg < 70\text{ mmHg} < 70 mmHg ) or alveolar-arterial ( A - a A\text{-}a A - a ) oxygen gradient ≥ 35 mmHg \ge 35\text{ mmHg} ≥ 35 mmHg to prevent fatal respiratory deterioration caused by the acute lysis of fungal organisms.
2. CURB-65 Prognostic Score & Antimicrobial Risk Stratification
The British Thoracic Society (BTS) and NICE endorse the validated CURB-65 scoring system to stratify 30-day mortality risk and guide admission and antibiotic decisions.
Variable Clinical Diagnostic Criterion Assigned Score
C — Confusion New mental confusion: Abbreviated Mental Test Score (AMTS) ≤ 8 \le 8 ≤ 8 , or new disorientation in person, place, or time 1
U — Urea Serum urea > 7.0 mmol/L > 7.0\text{ mmol/L} > 7.0 mmol/L (reflects dehydration, catabolism, or sepsis-induced AKI) 1
R — Respiratory Rate Tachypnoea with respiratory rate ≥ 30 breaths/min \ge 30\text{ breaths/min} ≥ 30 breaths/min 1
B — Blood Pressure Systolic blood pressure SBP < 90 mmHg \text{SBP} < 90\text{ mmHg} SBP < 90 mmHg OR Diastolic blood pressure DBP ≤ 60 mmHg \text{DBP} \le 60\text{ mmHg} DBP ≤ 60 mmHg 1
- 65 — Age Patient age ≥ 65 years \ge 65\text{ years} ≥ 65 years 1
- Risk Stratification & Recommended Antibiotic Regimens
CURB-65 Score 30-Day Mortality Recommended Care Setting First-Line Antimicrobial Regimens (NICE Guidelines)
0 – 1 < 3 % < 3\% < 3% Suitable for outpatient / community management Oral amoxicillin 500 mg 500\text{ mg} 500 mg three times daily for 5 days.; (Penicillin allergy: oral doxycycline 200 mg 200\text{ mg} 200 mg loading then 100 mg 100\text{ mg} 100 mg od, or oral clarithromycin 500 mg 500\text{ mg} 500 mg bd)
2 ≈ 9 % \approx 9\% ≈ 9% Inpatient general medical ward admission (or closely supervised outpatient care) Dual therapy with oral/IV amoxicillin 500 mg 500\text{ mg} 500 mg tds PLUS a macrolide (oral/IV clarithromycin 500 mg 500\text{ mg} 500 mg bd).; (Penicillin allergy: oral/IV levofloxacin 500 mg 500\text{ mg} 500 mg od)
3 – 5 15 – 40 % 15\text{–}40\% 15 – 40% Urgent inpatient admission ; immediately assess for HDU / ICU admission Intravenous co-amoxiclav 1.2 g 1.2\text{ g} 1.2 g three times daily PLUS intravenous clarithromycin 500 mg 500\text{ mg} 500 mg twice daily.; (Alternative: IV cefuroxime/ceftriaxone PLUS IV clarithromycin; Penicillin allergy: IV levofloxacin 500 mg 500\text{ mg} 500 mg bd)
3. Bronchiectasis: Aetiology & Pathophysiological Workup
Bronchiectasis is a chronic, irreversible abnormal dilation and distortion of the bronchi resulting from a self-perpetuating vicious cycle of impaired mucociliary clearance, chronic bacterial colonization, persistent transmural neutrophilic inflammation, and progressive destruction of the bronchial muscular and elastic structural components (Cole's vicious cycle hypothesis).
Underlying Aetiologies
Post-Infective (~30%): Severe necrotizing childhood infections (measles, pertussis, adenovirus, pulmonary tuberculosis, or severe childhood pneumonia).
Cystic Fibrosis (CF): Autosomal recessive mutation in the CFTR gene (chromosome 7, Δ F508 \Delta\text{F508} Δ F508 most common), causing defective cyclic AMP-dependent chloride transport across epithelial surfaces, dehydrated viscous mucus, recurrent infections ( S. aureus , P. aeruginosa ), pancreatic exocrine insufficiency, and predominantly upper lobe bronchiectasis .
Primary Ciliary Dyskinesia (PCD) / Kartagener Syndrome: Autosomal recessive mutations in ciliary ultrastructural proteins (outer or inner dynein arms). Kartagener syndrome features the classic clinical triad of:
Bronchiectasis (predominantly affecting the middle and lower lobes ).
Situs inversus / Dextrocardia (caused by absent embryonic nodal ciliary rotation).
Chronic pansinusitis and nasal polyposis, accompanied by male infertility (immotile sperm flagella) and subfertility in females.
Allergic Bronchopulmonary Aspergillosis (ABPA): Hypersensitivity reaction to colonized Aspergillus fumigatus in patients with underlying asthma or cystic fibrosis. Key features: Fleeting pulmonary infiltrates, central/proximal bronchiectasis with normal peripheral bronchi, expectoration of thick brown mucus plugs containing fungal hyphae, peripheral blood eosinophilia ( > 0.5 × 10 9 / L > 0.5 \times 10^9/\text{L} > 0.5 × 1 0 9 / L ), markedly elevated total serum IgE > 1000 IU/mL \text{IgE} > 1000\text{ IU/mL} IgE > 1000 IU/mL , and positive specific IgE/IgG to Aspergillus . Treatment: Oral prednisolone combined with oral itraconazole.
Immunodeficiency Syndromes: Primary hypogammaglobulinaemia (Common Variable Immunodeficiency [CVID], X-linked agammaglobulinaemia [Bruton's], selective IgA deficiency, IgG subclass deficiency) and secondary immunodeficiency (HIV, post-chemotherapy).
Connective Tissue Diseases: Rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus.
Alpha-1-Antitrypsin (AAT) Deficiency: Associated with basal panacinar emphysema and bronchiectasis.
Clinical Presentation & Diagnostic Investigations
Symptoms: Chronic daily cough productive of copious, purulent sputum (often layered into three distinct zones upon standing: frothy top layer, turbid liquid middle layer, and thick purulent sediment), recurrent febrile chest infections, dyspnoea, and intermittent haemoptysis (arising from hypertrophied, friable bronchial arteries).
Physical Signs: Coarse, pan-inspiratory or 'popping' crackles auscultated over the affected lung bases; coarse expiratory rhonchi; and digital clubbing (present in up to 30 % 30\% 30% ).
High-Resolution CT (HRCT) of the Chest: Gold Standard:
The "Signet Ring" Sign: Internal lumen diameter of a bronchus exceeds the diameter of its accompanying pulmonary artery branch (bronchoarterial ratio > 1.0 > 1.0 > 1.0 ).
Lack of bronchial tapering: Bronchi fail to taper progressively towards the lung periphery (bronchial walls visible within 1 cm 1\text{ cm} 1 cm of the costal pleura).
Bronchial wall thickening and mucus plugging (producing a "tree-in-bud" appearance reflecting active bronchiolitis).
Multidisciplinary Management & Pseudomonas aeruginosa Colonization
Airway Clearance Techniques (Physiotherapy): The non-pharmacological cornerstone of therapy. Daily or twice-daily chest physiotherapy incorporating the Active Cycle of Breathing Techniques (ACBT), postural drainage, and oscillatory positive expiratory pressure (OPEP / Flutter / Acapella devices) to dislodge secretions.
Mucoactive Agents: Inhaled nebulised hypertonic saline ( 6 – 7 % 6\text{–}7\% 6 – 7% ) or carbocisteine to reduce sputum viscosity.
Prophylactic Long-Term Antibiotics: In patients suffering ≥ 3 \ge 3 ≥ 3 acute exacerbations per year, long-term prophylactic macrolide therapy (oral azithromycin 250 mg 250\text{ mg} 250 mg three times weekly ) significantly reduces exacerbation rates through anti-inflammatory and immunomodulatory mechanisms. (Mandatory baseline ECG to exclude prolonged QTc, and sputum mycobacterial culture to exclude occult non-tuberculous mycobacteria [NTM], which would develop macrolide resistance).
Management of Pseudomonas aeruginosa Colonization:
Colonization by P. aeruginosa accelerates lung function decline, triples hospitalization risk, and doubles mortality.
First Isolation Eradication Protocol: Immediate, aggressive attempt at eradication is mandatory upon the very first isolate. Regimens combine high-dose oral ciprofloxacin ( 750 mg 750\text{ mg} 750 mg twice daily for 14 days) or IV antipseudomonal β \beta β -lactams (piperacillin-tazobactam or ceftazidime) with nebulised colistimethate sodium or tobramycin for up to 3 months.
Chronic Colonization: Maintenance long-term inhaled nebulised colistimethate or tobramycin to suppress bacterial load.